Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility

Molino, Suzanne; Martin, Michelle T.

doi:10.1177/1060028017704857

Cited by 7 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in 2017, the US Food and Drug Administration approved pan-genotypic DAA regimens with a high genetic barrier to resistance [ 25 ]. These regimens included the NS3/4A protease inhibitor pibrentasvir plus the NS5A inhibitor glecaprevir (GLE/PIB; AbbVie, North Chicago, IL, USA) and the NS5B polymerase inhibitor sofosbuvir in combination with the NS5A inhibitor velpatasvir plus the NS3/4A protease inhibitor voxilaprevir (SOF/VEL/VOX; Gilead Sciences, Foster City, CA, USA).…”

Section: Discussionmentioning

confidence: 99%

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan

Tsai

Hung

et al. 2021

Biomedical Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan

Tsai

Hung

et al. 2021

Biomedical Journal

View full text Add to dashboard Cite

“…Since 2015, several DAA IFN-free regimens have been approved [ 50 ]. In 2017, the US Food and Drug Administration (FDA) approved a therapy effective against all HCV genotypes (pan-genotypic treatment) [ 53 ]. Effective and safe DAA combinations can eradicate the virus in both previously treated and treatment-naïve patients, with more than 95% subjects achieving SVR [ 7 ].…”

Section: Gut Microbiota and Hcv Therapymentioning

confidence: 99%

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview

Marascio

Quirino

et al. 2022

JCM

View full text Add to dashboard Cite

Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut–liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut–liver axis.

show abstract

“…Some IFN-free regimens may provide broad coverage for all six major genotypes after 12 weeks of treatment [16], however according to drugs availability on the different countries [17]. Lastly, in 2017, the US Food and Drug Administration approved a pan-genotypic therapy with a high genetic barrier to resistance [18] that is the number of nucleotide changes requested to develop resistance.…”

Section: First Question: “Are Clinical Trials Fully Informative On Pamentioning

confidence: 99%

“…Resistance testing for treatment of HCV is suggested for HCV GT1a at Q80K position on NS3 target region [10] and HCV GT1a/HCV3 at 28, 30, 31, 58 and 93 positions on NS5A target region [10,14], in which the presence of RASs are clinically relevant for treatment choice and outcome during the first line therapy and retreatment [43]. Indeed, patients whose HCV harbors RASs on NS5A are very difficult to re-treat [18], because these mutations persist for years after failure for genetic reasons not yet clarified [12]. This kind of situations opens a new possibility of transmission of HCV resistant strains.…”

Section: Second Question: “Are Resistance Assays Important In Clinicamentioning

confidence: 99%

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

et al. 2019

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.

show abstract

Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility

Cited by 7 publications

References 8 publications

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan

The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Contact Info

Product

Resources

About